Literature DB >> 23758581

Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.

Sobhan Faezi1, Maryam Safarloo, Nour Amirmozafari, Iraj Nikokar, Seyed Davar Siadat, Ian Alan Holder, Mehdi Mahdavi.   

Abstract

The main goal of this study was to develop a vaccination strategy that would enhance the protective response against the recombinant type A flagellin (r-fla-A) of Pseudomonas aeruginosa in the burn wound sepsis model. Inbred mice were immunized with r-fla-A with or without alum adjuvant. The vaccinated mice were burned and challenged with P. aeruginosa. To evaluate the type of induced immune response, sera were analyzed by ELISA for total IgG, IgG1, and IgG2a isotypes. To determine the functional activity of anti r-fla IgG, opsonophagocytic killing and motility inhibition assay was performed. In vivo administration of r-fla-A afforded a remarkable improvement in survival of mice (83.3%) challenged with homologous strain (PAK) in the burn wound infection. The antibodies generated against the r-fla-A achieved 25% survival in immunized mice that had been infected with heterologous strain PAO1. Flagellin also induced high level humoral immune response via high titers of serum IgG1 in the burn and challenged mice. Anti r-fla-A antibody promoted phagocytosis of the PAK strain, and the number of viable bacterial cells decreased over 53.1%; In contrast, low opsonophagocytic killing activity (17.4%) was observed when the antiserum to r-fla-A was treated with the PAO1 strain. The anti r-fla-A antisera was able to inhibit the motility of the homologous strains; however, they did not inhibit the heterologous strains. We concluded that active immunization with recombinant type A-flagellin could protect burn mice against lethal P. aeruginosa challenge via immobilization of the pathogen which promoted the phagocytic activity.
© 2013 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Pseudomonas aeruginosa; burn; flagellin; immunization

Mesh:

Substances:

Year:  2013        PMID: 23758581     DOI: 10.1111/apm.12101

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  12 in total

1.  Correlation of occurrence of infection in burn patients.

Authors:  N A Latifi; H Karimi
Journal:  Ann Burns Fire Disasters       Date:  2017-09-30

2.  Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: protectivity in murine model.

Authors:  Leila Safari Zanjani; Reza Shapouri; Mehrouz Dezfulian; Mehdi Mahdavi; Mehdi Shafiee Ardestani
Journal:  World J Microbiol Biotechnol       Date:  2019-06-11       Impact factor: 4.253

3.  Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections.

Authors:  Cory M Robinson; Brianna N Kobe; Deanna M Schmitt; Brian Phair; Tricia Gilson; Joo-Yong Jung; Lawton Roberts; Jialin Liao; Chelsea Camerlengo; Brandon Chang; Mackenzie Davis; Leah Figurski; Devin Sindeldecker; Joseph Horzempa
Journal:  Bioengineered       Date:  2015       Impact factor: 3.269

4.  The Frequency of Exotoxin A and Exoenzymes S and U Genes Among Clinical Isolates of Pseudomonas aeruginosa in Shiraz, Iran.

Authors:  Arshid Yousefi-Avarvand; Reza Khashei; Hadi Sedigh Ebrahim-Saraie; Amir Emami; Kamiar Zomorodian; Mohammad Motamedifar
Journal:  Int J Mol Cell Med       Date:  2015

5.  Potentiation of human papilloma vaccine candidate using naloxone/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine.

Authors:  Mahsa Yasaghi; Mehdi Mahdavi
Journal:  Iran J Basic Med Sci       Date:  2016-09       Impact factor: 2.699

6.  A scalable method for biochemical purification of Salmonella flagellin.

Authors:  Raphael Simon; Brittany Curtis; Vehid Deumic; Jennifer Nicki; Sharon M Tennant; Marcela F Pasetti; Andrew Lees; Philip W Wills; Marco Chacon; Myron M Levine
Journal:  Protein Expr Purif       Date:  2014-07-19       Impact factor: 1.650

7.  High Yield Overexpression, Refolding, Purification and Characterization of Pseudomonas aeruginosa Type B-Flagellin: An Improved Method Without Sonication.

Authors:  Sobhan Faezi; Ahmad Reza Bahrmand; Mehdi Mahdavi; Seyed Davar Siadat; Iraj Nikokar; Soroush Sardari; Ian Alan Holder
Journal:  Int J Mol Cell Med       Date:  2016

8.  Evaluation of the Immunogenicity of Diphtheria Toxoid Conjugated to Salmonella Typhimurium-Derived OPS in a Mouse Model: A Potential Vaccine Candidate Against Salmonellosis.

Authors:  Vahid Amini; Hossein Kazemian; Jalil Kardan Yamchi; Seifu Gizaw Feyisa; Saeed Aslani; Aref Shavalipour; Hamidreza Houri; Mohammadneshvan Hoorijani; Mehrdad Halaji; Hamid Heidari
Journal:  Iran Red Crescent Med J       Date:  2016-05-30       Impact factor: 0.611

9.  Development of a Novel Anti-Adhesive Vaccine Against Pseudomonasaeruginosa Targeting the C-terminal Disulfide Loop of the Pilin Protein.

Authors:  Sobhan Faezi; Ahmad Reza Bahrmand; Mehdi Mahdavi; Seyed Davar Siadat; Iraj Nikokar; Soroush Sardari
Journal:  Int J Mol Cell Med       Date:  2017-05-31

10.  Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa.

Authors:  Nicolas Hegerle; Myeongjin Choi; James Sinclair; Mohammed N Amin; Morgane Ollivault-Shiflett; Brittany Curtis; Rachel S Laufer; Surekha Shridhar; Jerod Brammer; Franklin R Toapanta; Ian Alan Holder; Marcela F Pasetti; Andrew Lees; Sharon M Tennant; Alan S Cross; Raphael Simon
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.